Paliperidon Krka (Paliperidone)

Paliperidone, the active ingredient in Paliperidon Krka, is an atypical antipsychotic presented as a tablet for oral use. It is used to treat schizophrenia and schizoaffective disorder in adults.

GNH USA supplies Paliperidon Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in serious mental health conditions. - Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse. - Schizoaffective disorder: Improves mood symptoms and psychotic features. - Maintenance therapy: Supports long‑term stability after an acute episode.

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Akathisia: Restlessness and an urge to move constantly. - Weight gain: Increased appetite leading to modest weight increase. - Somnolence: Drowsiness or fatigue. - Dry mouth: Reduced salivation causing oral dryness. - Constipation: Slowed gastrointestinal motility. - Elevated prolactin: Menstrual changes or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Persistent involuntary movements. - Seizures: Increased risk, especially at higher doses. - Orthostatic hypotension: Marked blood‑pressure drop on standing. - Hyperglycaemia: Elevated blood‑sugar levels, may worsen diabetes. - Cardiac arrhythmias: QT‑interval prolongation leading to rhythm disturbances.

When prescribing Paliperidone, clinicians should evaluate patient history and monitor for specific safety concerns. - Cardiovascular assessment: Baseline ECG and periodic monitoring for QT prolongation. - Metabolic monitoring: Check weight, fasting glucose and lipid profile regularly. - Movement disorders: Observe for early signs of tardive dyskinesia or akathisia. - Pregnancy and lactation: Use only if benefits outweigh risks; discuss with obstetric specialist. - Drug‑interaction review: Assess concomitant medications that affect CYP450 enzymes. - Store at below 25°C: Keep in the original container, protect from moisture and direct sunlight.

Paliperidone can interact with several medicines that influence its metabolism or additive pharmacodynamic effects.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase paliperidone exposure. - QT‑prolonging agents (e.g., sotalol, quinidine): Heighten risk of cardiac arrhythmias. - CNS depressants (e.g., benzodiazepines, opioids): May amplify sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampicin): May reduce paliperidone levels. - Antihistamines with anticholinergic properties (e.g., diphenhydramine): May worsen dry mouth. - Antidiabetic drugs: Monitor glucose as paliperidone can affect glycaemic control.